Given that host-directed therapies aimed at improving control of infectious diseases are likely to be used in association with conventional anti-parasitic drugs, we tested anti-IFNαR1 mAb treatment with and without a suboptimal dose of Ambisome, the first-line drug for treating VL in India (Sundar et al., 2010). The gene discussed is IFNAR1; the disease is infectious disease.